Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 89
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: MORAb-009-003 Amatuximab
Study First Received: August 19, 2008
Last Updated: November 13, 2015
Estimated Primary Completion Date: June 2011
Primary Outcome Measures:
Progression free survival using the EORTC modified RECIST criteria.|Overall response, duration of survival, overall survival and safety.
Sponsors and Collaborators:
Morphotek
Website Link: https://ClinicalTrials.gov/show/NCT00738582
